1
|
Min B, Yoo M, Kim H, Cho M, Nam DH, Yoon Y. Semi-Automated Cell Panning for Efficient Isolation of FGFR3-Targeting Antibody. Int J Mol Sci 2021; 22:ijms22126240. [PMID: 34207911 PMCID: PMC8229736 DOI: 10.3390/ijms22126240] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2021] [Revised: 06/03/2021] [Accepted: 06/07/2021] [Indexed: 12/24/2022] Open
Abstract
Phage display technology is a widely used practical tool for isolating binding molecules against the desired targets in phage libraries. In the case of targeting the membrane protein with its natural conformation, conventional bio-panning has limitations on the efficient screening of the functionally relevant antibodies. To enrich the single-chain variable fragment (scFv) pools for recognizing the natural conformation of the membrane targets, the conventional bio-panning and screening process was modified to include the semi-automated cell panning protocol. Using FGFR3-overexpressing patient-derived cancer cells, biotin-X-DHPE was introduced and coupled to Streptavidin-coated magnetic beads for use in the solution-phage bio-panning procedure. The resulting clones of scFv were compared to the diversity of the binding region, especially on CDR-H3. The clones enriched further by cell-based panning procedure possessed a similar binding site and the CDR-H3 loop structure. The resulting antibodies inhibited cell growth and induced target degradation. This process may be a useful tool for screening biologically related antibodies that recognize natural conformational structure on cell membrane protein. Furthermore, cell-based panning has the potential to further expand to a high-throughput screening (HTS) system and automation process.
Collapse
Affiliation(s)
- Byeongkwi Min
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul 06351, Korea; (B.M.); (H.K.)
- Institute for Refractory Cancer Research, Research Institute for Future Medicine, Samsung Medical Center, Seoul 06351, Korea; (M.Y.); (M.C.)
| | - Minyoung Yoo
- Institute for Refractory Cancer Research, Research Institute for Future Medicine, Samsung Medical Center, Seoul 06351, Korea; (M.Y.); (M.C.)
| | - Hyeree Kim
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul 06351, Korea; (B.M.); (H.K.)
- Institute for Future Medicine, Samsung Medical Center, Seoul 06351, Korea
| | - Minjung Cho
- Institute for Refractory Cancer Research, Research Institute for Future Medicine, Samsung Medical Center, Seoul 06351, Korea; (M.Y.); (M.C.)
| | - Do-Hyun Nam
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul 06351, Korea; (B.M.); (H.K.)
- Institute for Refractory Cancer Research, Research Institute for Future Medicine, Samsung Medical Center, Seoul 06351, Korea; (M.Y.); (M.C.)
- Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea
- Correspondence: (D.-H.N.); (Y.Y.); Tel.: +82-(2)-3410-3497 (D.-H.N.); +82-(2)-2148-7900 (Y.Y.)
| | - Yeup Yoon
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul 06351, Korea; (B.M.); (H.K.)
- Institute for Refractory Cancer Research, Research Institute for Future Medicine, Samsung Medical Center, Seoul 06351, Korea; (M.Y.); (M.C.)
- Institute for Future Medicine, Samsung Medical Center, Seoul 06351, Korea
- Department of Biopharmaceutical Convergence, Sungkyunkwan University, Seoul 06351, Korea
- Correspondence: (D.-H.N.); (Y.Y.); Tel.: +82-(2)-3410-3497 (D.-H.N.); +82-(2)-2148-7900 (Y.Y.)
| |
Collapse
|